Eisai And Shionogi Develop Obesity Drug Meridia In Japan
This article was originally published in PharmAsia News
Executive Summary
Major drug maker Eisai is aiming to launch its obesity drug Meridia (sibutramine) in two to three years. Eisai signed a licensing deal with U.S. major drug maker Abbott Laboratories and obtained exclusive rights to develop and market the drug in Japan. According to Eisai, Japanese domestic clinical trials have shown efficacy in weight loss. The company has submitted an NDA with the Ministry of Health, Labor and Welfare. Shionogi also plans to develop an obesity agent in 10 years. (Click here for more - Japanese language